Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness

Background/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who recovered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization). It is a challenge to find suitable donors. The aim of the st...

Full description

Saved in:
Bibliographic Details
Main Authors: Grujić Jasmina, Bujandrić Nevenka, Budakov-Obradović Zorana, Savić Nebojša, Dolinaj Vladimir
Format: Article
Language:English
Published: Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade 2022-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2022/0042-84502200094G.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849685656974917632
author Grujić Jasmina
Bujandrić Nevenka
Budakov-Obradović Zorana
Savić Nebojša
Dolinaj Vladimir
author_facet Grujić Jasmina
Bujandrić Nevenka
Budakov-Obradović Zorana
Savić Nebojša
Dolinaj Vladimir
author_sort Grujić Jasmina
collection DOAJ
description Background/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who recovered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization). It is a challenge to find suitable donors. The aim of the study was to successively monitor antibody titer in donations and to investigate the correlation between antibody titer and the severity of the clinical manifestations. Methods. The retrospective study was conducted from May 1 to October 31, 2020, at the Blood Transfusion Institute of Vojvodina. Donors had to meet certain criteria for inclusion in the study: proven SARS-CoV-2 infection, detected SARS-CoV-2 antibodies in the serum/plasma, fulfillment of general criteria for performing plasmapheresis, and adequate laboratory findings. Results. During the study, 651 apheresis plasma units were collected and divided into two equal doses. Plasma was donated by 311 COVID- 19 convalescents, including 208 (66.9%) men and 103 (33.1%) women. There were 15 (4.8%) plasma donors with asymptomatic infection, 235 (75. 6%) with a mild form of illness, 45 (14.5%) with a moderate form of illness, 16 (5.1%) with a severe form of illness, and none with a critical form of illness. Anti-SARS-CoV-2 IgG antibodies were present in the plasma of donors for more than 6 months after the disease. Plasma donors with a more severe clinical manifestation of COVID-19 had stable antibody levels for a longer period. However, the Pearson correlation of clinical severity and antibody titer did not confirm a statistically significant correlation between the variables. Conclusion. Anti-SARS-CoV-2 antibodies were present in the sample of recovered patients, plasma donors, for more than 6 months after the disease. Even though no statistically significant correlation was found between the anti-SARS-CoV-2 anti-body titer and the clinical severity of COVID-19, in patients with a more severe clinical manifestations of the disease, stable antibody levels were maintained for a longer period.
format Article
id doaj-art-bea678c31ce64130bc7e84b9eaf3847d
institution DOAJ
issn 0042-8450
2406-0720
language English
publishDate 2022-01-01
publisher Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
record_format Article
series Vojnosanitetski Pregled
spelling doaj-art-bea678c31ce64130bc7e84b9eaf3847d2025-08-20T03:23:02ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202022-01-0179121201120810.2298/VSP210301094G0042-84502200094GAnti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illnessGrujić Jasmina0https://orcid.org/0000-0003-3092-4768Bujandrić Nevenka1Budakov-Obradović Zorana2Savić Nebojša3Dolinaj Vladimir4https://orcid.org/0000-0002-2092-5479Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia + University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, SerbiaBlood Transfusion Institute of Vojvodina, Novi Sad, Serbia + University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, SerbiaBlood Transfusion Institute of Vojvodina, Novi Sad, Serbia + University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, SerbiaUniversity Clinical Center of Serbia, Clinic for Vascular and Endovascular Surgery, Department of Transfusion Medicine, Belgrade, SerbiaUniversity Clinical Center of Vojvodina, Department of Anesthesiology, Novi Sad, Serbia + University of Novi Sad, Faculty of Medicine, Department of Health Care, Novi Sad, SerbiaBackground/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who recovered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization). It is a challenge to find suitable donors. The aim of the study was to successively monitor antibody titer in donations and to investigate the correlation between antibody titer and the severity of the clinical manifestations. Methods. The retrospective study was conducted from May 1 to October 31, 2020, at the Blood Transfusion Institute of Vojvodina. Donors had to meet certain criteria for inclusion in the study: proven SARS-CoV-2 infection, detected SARS-CoV-2 antibodies in the serum/plasma, fulfillment of general criteria for performing plasmapheresis, and adequate laboratory findings. Results. During the study, 651 apheresis plasma units were collected and divided into two equal doses. Plasma was donated by 311 COVID- 19 convalescents, including 208 (66.9%) men and 103 (33.1%) women. There were 15 (4.8%) plasma donors with asymptomatic infection, 235 (75. 6%) with a mild form of illness, 45 (14.5%) with a moderate form of illness, 16 (5.1%) with a severe form of illness, and none with a critical form of illness. Anti-SARS-CoV-2 IgG antibodies were present in the plasma of donors for more than 6 months after the disease. Plasma donors with a more severe clinical manifestation of COVID-19 had stable antibody levels for a longer period. However, the Pearson correlation of clinical severity and antibody titer did not confirm a statistically significant correlation between the variables. Conclusion. Anti-SARS-CoV-2 antibodies were present in the sample of recovered patients, plasma donors, for more than 6 months after the disease. Even though no statistically significant correlation was found between the anti-SARS-CoV-2 anti-body titer and the clinical severity of COVID-19, in patients with a more severe clinical manifestations of the disease, stable antibody levels were maintained for a longer period.http://www.doiserbia.nb.rs/img/doi/0042-8450/2022/0042-84502200094G.pdfantibody formationblood donorscovid-19 serotherapyimmunization, passiveplasma
spellingShingle Grujić Jasmina
Bujandrić Nevenka
Budakov-Obradović Zorana
Savić Nebojša
Dolinaj Vladimir
Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness
Vojnosanitetski Pregled
antibody formation
blood donors
covid-19 serotherapy
immunization, passive
plasma
title Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness
title_full Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness
title_fullStr Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness
title_full_unstemmed Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness
title_short Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness
title_sort anti sars cov 2 antibody responses in convalescent plasma donors with varying severity of covid 19 illness
topic antibody formation
blood donors
covid-19 serotherapy
immunization, passive
plasma
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2022/0042-84502200094G.pdf
work_keys_str_mv AT grujicjasmina antisarscov2antibodyresponsesinconvalescentplasmadonorswithvaryingseverityofcovid19illness
AT bujandricnevenka antisarscov2antibodyresponsesinconvalescentplasmadonorswithvaryingseverityofcovid19illness
AT budakovobradoviczorana antisarscov2antibodyresponsesinconvalescentplasmadonorswithvaryingseverityofcovid19illness
AT savicnebojsa antisarscov2antibodyresponsesinconvalescentplasmadonorswithvaryingseverityofcovid19illness
AT dolinajvladimir antisarscov2antibodyresponsesinconvalescentplasmadonorswithvaryingseverityofcovid19illness